Zenabis Global (TSX:ZENA) has agreed to supply cannabis extracts for PAX Era pods, which are designed for use with PAX Labs’ Era vaporizer device. Under the accord, Zenabis will supply cannabis extracts in the form...
Stifel downgraded Concert Pharmaceuticals (NASDAQ:CNCE) to “hold” from “buy” and lowered its price target to $8 from $18 after the company reported a Phase 3 trial failure with its AVP-786 drug candidate in Alzheimer’s...
Cheryl Reicin, partner at Torys, was named Canada’s financial and corporate attorney of the year at the seventh annual LMG Life Sciences awards. Ms. Reicin is the practice leader of Torys’ life science group...
H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its proprietary family...
IntelGenx (TSXV:IGX; OTCQX:IGXT) resubmitted its 505(b)(2) new drug application for RIZAPORT VersaFilM for the treatment of acute migraines to the FDA. “Over the past several months, we have been working diligently to...
Several large laboratories have successfully completed validation studies to test Precipio’s (NASDAQ:PRPO) IV-Cell cytogenetics media product, as well as its HemeScreen assay, and are proceeding towards placing orders...
Cortexyme (NASDAQ:CRTX) began screening patients in Europe for its international Phase 2/3 trial, called GAIN, to evaluate COR388 in patients with mild-to-moderate Alzheimer’s disease (AD). The company has been...
Marinus Pharmaceuticals (NASDAQ:MRNS) reported positive topline results from its Phase 2 trial of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). Status epilepticus is a prolonged...
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) recently met with the FDA to discuss its premarket approval regulatory pathway for marketing authorization of its i/Blue Imaging System. Based...
H.C. Wainwright upgraded Bionomics (ASX:BNO) to “buy” from “neutral” and raised its price target to 30c (Australian) from three cents after the company announced results of a pharmacokinetics (PK) study of the tablet...
UroGen Pharma (NASDAQ:URGN) reported results from its Phase 3 and Phase 2b trials of its mitomycin gel in patients with low-grade upper tract urothelial cancer (UTUC) and intermediate risk low-grade non-muscle invasive...
Andrew Komjathy Catabasis Pharmaceuticals (NASDAQ:CATB) appointed Andrew Komjathy as its chief commercial officer. Catabasis’ lead program is edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). The...